RetmarkerDR is a biomarker for Diabetic Retinopathy progression in a mild non-proliferative stage, predicting sight threatening Diabetic Retinopathy through the quantification of microaneurysms turnover ratios, namely for Clinically Significant Macular Edema.
There is a FREE Trial of RetmarkerDR available for download that entitles each user to install the software and process 20 free analysis (sets of images).
According to our research, where we analysed different type 2 diabetic patients with non-proliferative retinopathy, Microaneurysm Turnover was a key factor for the classification in different phenotypes and appears to be a good predictor of progression to Clinically Significant Macular Edema (CSME).
Professor Conceição Lobo, Leading ophthalmologist and researcher from the University Hospital of Coimbra, Portugal
RetmarkerDR consistently tracks each microaneurysm as a single entity in a specific location, with identifiable coordinates, providing valuable information:
- RetmarkerDR colour-codes microaneurysms, classifying each one as NEW (red colour), OLD (green colour) or DISAPPEARED (yellow colour).
- RetmarkerDR allows detailed examination of the patients’ fundus photographs allowing, for example, to make measures on each subfield and insert comments and manual annotations (including exudates, hemorrhages and other lesions).
- RetmarkerDR also allows the user to add new microaneurysms or even removing the automatically detected ones without ever compromising the automated results generated by the software.
Tracking Microaneurysms over time
Detailed image analysis and annotation in the Image Explorer
Extend the automated results with manually marked Microaneurysms
With the microaneurysm turnover information, in a mild non proliferative stage of Diabetic Retinopathy, before the development of complications (either being diabetic macular edema or proliferative Diabetic Retinopathy) it is possible to predict the evolution of the disease for a Clinically Significant Macular Edema stage.
Recent findings from AIBILI supports that a follow-up at regular intervals (6 months suggested) in the early stages of diabetic retinopathy (before development of complications) can be used to predict the eyes that are at risk of progression into CSME.
RetmarkerDR integrates in the practice workflow and can also be used by technicians operating the fundus camera reducing the time doctors need to spend looking at the patient’s exams.
All the information can be printed in a report that can go to the Patient Clinical Record or even be given to the patient.
You can access more information on this product version by downloading the official brochure here.